Platform can help uncover how aging contributes to disease and identify epigenetic biomarkers that guide the development of new interventions.
Swedish biotech Epigenica this week secured $2.2 million in funding to accelerate the commercialization of its high-throughput epigenetic technologies and expand its market presence, particularly in the United States. The company’s core technology enables simultaneous analysis of multiple epigenetic markers across a wide array of sample types, and has the potential to help advance the longevity field.
Epigenetics refers to the study of changes in gene expression that do not involve alterations to the underlying DNA sequence. These changes, which can be triggered by environmental factors, aging, or disease states, influence how genes are turned on or off and can play a role in the onset and progression of various conditions. In drug development for age-related diseases, epigenetics offers a powerful lens to understand how cellular function declines over time and contributes to diseases such as cancer, neurodegeneration and cardiovascular disorders.

The broader scientific landscape is increasingly embracing multi-omics as a comprehensive approach to understanding complex biological systems. Epigenetics provides an essential regulatory layer that complements data from genomics, transcriptomics, proteomics and metabolomics. As a result, demand is rising for scalable technologies that can interrogate the epigenome with precision and speed.
However, according to Epigenica, most existing epigenetic tools are limited by low throughput, high costs and the inability to combine DNA methylation and histone modification data in a single workflow. The company says its EpiFinder platform offers a unified, scalable solution that enables researchers to conduct quantitative, genome-wide epigenomic profiling using minimal input material, supporting applications in drug development, precision medicine and, of course, longevity research.
“Aging is a major risk factor for diseases like cancer, neurodegeneration and cardiovascular disease, yet the underlying epigenetic changes remain underexplored,” Epigenica’s CEO Dr Mohamad Takwa told us. “By enabling precise and scalable measurement of these changes, Epigenica’s platform can help researchers uncover how aging contributes to disease and identify biomarkers that guide the development of new interventions. We see our technology as a way to accelerate the translation of longevity research into practical strategies that can improve health as we age.”
Epigenica claims its flagship product, EpiFinder Genome, is the first commercial kit to provide high-throughput, multiplex ChIP-seq capabilities. It allows researchers to analyze up to eight epigenetic markers across 24 samples in one workflow, producing 192 genome-wide profiles with efficiency and consistency. This allows for robust and replicable data generation at a scale and speed previously unattainable with conventional approaches. EpiFinder Genome is compatible with a wide range of sample types, including primary cells, cultured cells and tissue, making it broadly applicable for both academic and commercial research.
Epigenica is also preparing to launch additional kits to further expand the capabilities of its platform. These new offerings are designed to support blood-based epigenomics and high-throughput screening across diverse epigenetic landscapes. At the same time, the company is building out its service and data infrastructure to better support partners in research and clinical development.
The round was led by Voima Ventures, and included participation from Navigare Ventures, Leksell Social Ventures and returning investor Almi Invest. This funding positions Epigenica to advance its product development, enhance its service offerings and scale up operations to meet growing global demand for innovative epigenomic research tools.
“The field of epigenetics, which studies how our lifestyle and environment impact the way our genes work, holds transformative potential in areas like oncology, longevity and drug development,” said Voima’s Stina Wallmark, Voima. “Epigenica enables fast, scalable and affordable analysis of epigenetic biomarkers, helping researchers fully unlock the potential of multi-omics in the search for new diagnostics and therapies.”
Photographs courtesy of Epigenica
The post Epigenica enables ‘precise and scalable measurement’ of epigenetic changes appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.